MLYS.US Mineralys Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
14.53 USD
Close of Nov 16, 2026
14.45 45.00
Market cap
USD 1.29B
P/E
-
P/B
2.70x
ROE
-89.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is MLYS.US undervalued?

Graham number

The Graham number of Mineralys Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Mineralys Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Mineralys Therapeutics, Inc. Common Stock yet.

Mineralys Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Mineralys Therapeutics, Inc. Common Stock

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. a…

Full company profile